Introduction
Valproate (VPA), is a drug of choice for patients with partial seizures with or without secondary generalization and it is also one of the most effective 
years).
Results: None had vigabatrin-type, concentric visual field defect with the kinetic Goldmann or automated Humphrey perimetries. In the Humphrey perimetry, the mean deviation for the group was within normal limits varying from À2.53 to 0.59 dB (À0.74 AE 0.80 dB) in the right eye and from À2.66 to 0.67 dB (À0.78 AE 0.82 dB) in the left eye.
In the FM100 test, acquired colour vision deficiency was found in two out of 18 patients (11%, 95% CI: 0-25%). However, the mean total error score was lower in the patient group than in the control group. All patients had normal contrast sensitivity function. Conclusions: The use of VPA in the treatment of epilepsy is not associated with visual field defects similar to vigabatrin, but may induce abnormalities in colour vision. antiepileptic drugs (AED) against generalized absence seizures.
1 Although the precise mechanisms of action of VPA is not well established, it is accepted that the drug affects the GABAergic system, resulting in elevated GABA levels in central nervous system. 1 GABAergic properties of VPA are involved in several pharmacodynamic effects of the drug including possible slight inhibition of GABA transaminase. Visual field constriction has been reported in epilepsy patients treated with a GABAergic AED, vigabatrin (VGB), an irreversible inhibitor of GABA transaminase. [2] [3] [4] A combination therapy with VGB and VPA in the treatment of epilepsy has been suggested to possess an increased risk for visual field loss. 3, 4 However, visual field defects or electrophysiological abnormalities were not found in 32 epilepsy patients on VPA monotherapy, 5 but acquired colour vision defects have been reported in association with VPA therapy. 6, 7 The concern arising from VGB-associated visual field defects prompted us to investigate the effects of VPA on visual function in epilepsy patients treated with initial VPA monotherapy.
Methods
This study was reviewed and accepted by the Ethics Committee of Kuopio University Hospital and the University of Kuopio, and was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki. All patients gave written informed consent.
Eighteen epilepsy patients (eight men, ten women) with initial VPA monotherapy participated in this cross-sectional study. The patients suffered from partial epilepsy with or without secondary generalisation (N = 8), from juvenile myoclonus epilepsy (N = 4) or other generalized tonic-clonic seizures (N = 6). All except one had VPA as their initial treatment; one patient had started on carbamazepine but had developed a hypersensitivity reaction and the therapy was soon switched to VPA. The patients had normal or mildly subnormal general intelligence and had been seizure free for several years. At the time of the epilepsy diagnosis, brain CT or MRI scans have been performed without findings that might interfere with visual fields.
A standard ophthalmologic examination including dilated indirect ophthalmoscopy and measurement of intraocular pressure with the Goldmann applanation tonometry was performed to exclude eye diseases. The peripheral visual field was examined with the kinetic Goldmann perimeter (Haag-Streit, Bern, Switzerland) using stimuli IV/4 and I/3. The central 308 field was examined with the automated static Humphrey Field Analyzer 750 (HFA, Humphrey Systems, Dublin, CA) using the 30-2 SITA Standard threshold strategy. The patient reliability was evaluated using the reliability indices of the HFA (<20% of fixation losses and <33% false positive and negative answers were accepted).
Colour vision was tested monocularly with two methods. To exclude congenital red-green colour vision defects, the Standard Pseudoisochromatic Plates Part 2 (SPP2) screening test 8 was performed prior to the Farnsworth-Munsell 100 Hue test (FM100). 9 The illumination was provided by a Macbeth Easel lamp, 1000 lx, and a near vision correction was used if needed. The error scores were calculated as square roots, 10 and the axis according to Smith et al. 11 The normal values by Mäntyjärvi Statistical analysis was performed with the SPSS/ PC program (SPSS Inc., Chicago, IL). A p value of <0.05 was considered significant.
Results
The ages of the patients varied from 18 to 50 years (30.2 AE 10 years). The ages of the patients and controls did not differ in contrast sensitivity and colour vision comparisons, whereas the control group in the visual field evaluation was older than the VPA group ( p = 0.004) due to previously collected material. The daily dose of VPA varied from 800 to 2000 mg (1156 AE 307 mg), the duration of therapy from 24 to 240 months (101 AE 61 months) and the cumulative dose from 720 to 9120 g (3580 AE 2309 g). The plasma concentrations of VPA varied from 171 to 787 mmol/l (439 AE 154 mmol/l). The best-corrected visual acuity was 20/25 or better in all eyes.
All kinetic visual fields of the VPA monotherapy patients were assessed clinically as normal. 2 A comparison of visual field extents between the patients and controls is presented in Table 1 .
In the automated static perimetry, the reliability indices were within generally accepted ranges. The mean deviation varied from À2.53 to 0.59 dB (À0.74 AE 0.80 dB) in the right eye and from À2.66 to 0.67 dB (À0.78 AE 0.82 dB) in the left eye (Fig. 1) . The pattern standard deviation varied from 1.24 to 2.52 dB (1.78 AE 0.37 dB) in the right eye and from 1.25 to 2.44 dB (1.66 AE 0.30 dB) in the left eye. The probability analysis of the HFA showed no points or clusters of p < 0.01 or <0.005 in the edges of 308 visual field indicating an absence of VGB-typed visual field defect. 2 All patients passed the SPP 2 test. Altogether, two patients of 18 (11%, 95% CI 0-25%) had blue axes in the FM 100 test in one or both eyes. The total error score was within the normal age-dependent ranges 12 in all patients. As a group, a significant difference was found between the VPA patients and controls (t-test, p = 0.004 in the right and p = 0.001 in the left eye), but surprisingly, the error scores were significantly lower in the patient group (right eye: 6.1 AE 2.6; left eye: 6.1 AE 2.7) than in the control group (right eye: 8.3 AE 2.6; left eye 8.4 AE 2.4). No correlation was found between the FM100 error scores and the duration of VPA therapy, the cumulative dose of VPA or the plasma concentrations of VPA.
Individual contrast sensitivity values were within normal limits. 13 As a group, the results between patients (right eye: 1.78 AE 0.1, range 1.65-1.95; left eye: 1.78 AE 0.1, range 1.65-1.95) and controls (right eye: 1.77 AE 0.1, range 1.5-1.95; left eye: 1.76 AE 0.1, range 1.65-1.95) did not differ.
Discussion
The results of the present study indicate that the use of VPA monotherapy in the treatment of epilepsy is not associated with visual field defects. This is in concordance with the previous study in epilepsy patients receiving long-term VPA monotherapy. 5 The characteristics of VGB-associated visual field defects have been established in several studies. [2] [3] [4] In the present study, both kinetic and automated static perimetries were performed to accurately find any visual field defects. Typical concentric or annular nasal visual field defects were not found by either method. On the contrary, VPA patients showed even wider kinetic fields than normal controls in some meridians. However, the VPA monotherapy patients were younger than the controls.
Our results confirm previous findings that VGBassociated visual field defects seem not to be a class-effect of GABAergic AEDs but VGB-specific phenomena. This opinion is supported also by two studies in which tiagabine, the anticonvulsant mechanism of which resembles most of all AEDs to that of VGB, has not been shown to cause visual field defects. 14, 15 On the basis of the GABAergic properties of VPA, it has been discussed that combination therapy with VGB and VPA might be particularly retinotoxic. 3, 4 The GABAergic properties of VPA are only a part of its mode of action, and it is unclear if and how VPA increases retinal toxicity of VGB. Accumulation of VGB and GABA in the retina has been suggested to be the mechanism of VGB retinotoxicity 16 but still, the exact mechanism has not been elucidated. In rodents, after administration of VPA, inhibition of nerve-terminal GABA-transaminase and increase in presynaptic GABA has been observed. 1 An additive inhibitory effect of VPA on GABA transaminase might be one explanation.
In the present study, contrast sensitivity tests did not reveal any abnormalities but, minor abnormalities in colour vision were found in two patients. In newly diagnosed epilepsy patients treated with VPA or carbamazepine for 1 year, a clear decline in both central and paracentral colour vision examined with the FM100 and Short Wavelength Automated Perimetry (SWAP) was reported. 6 This may indicate general retinotoxicity related to the use of AEDs, but affecting mainly short wavelength sensitive cones. 7 Nevertheless, the colour vision deficit associated with the use of VPA is mostly subclinical, does not affect visual performance in the everyday life of epilepsy patients and therefore does not require monitoring.
